Literature DB >> 24616478

Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells.

Alfredo Caro-Maldonado1, Ruoning Wang, Amanda G Nichols, Masayuki Kuraoka, Sandra Milasta, Lillian D Sun, Amanda L Gavin, E Dale Abel, Garnett Kelsoe, Douglas R Green, Jeffrey C Rathmell.   

Abstract

B cell activation leads to proliferation and Ab production that can protect from pathogens or promote autoimmunity. Regulation of cell metabolism is essential to support the demands of lymphocyte growth and effector function and may regulate tolerance. In this study, we tested the regulation and role of glucose uptake and metabolism in the proliferation and Ab production of control, anergic, and autoimmune-prone B cells. Control B cells had a balanced increase in lactate production and oxygen consumption following activation, with proportionally increased glucose transporter Glut1 expression and mitochondrial mass upon either LPS or BCR stimulation. This contrasted with metabolic reprogramming of T cells, which had lower glycolytic flux when resting but disproportionately increased this pathway upon activation. Importantly, tolerance greatly affected B cell metabolic reprogramming. Anergic B cells remained metabolically quiescent, with only a modest increase in glycolysis and oxygen consumption with LPS stimulation. B cells chronically stimulated with elevated BAFF, however, rapidly increased glycolysis and Ab production upon stimulation. Induction of glycolysis was critical for Ab production, as glycolytic inhibition with the pyruvate dehydrogenase kinase inhibitor dichloroacetate sharply suppressed B cell proliferation and Ab secretion in vitro and in vivo. Furthermore, B cell-specific deletion of Glut1 led to reduced B cell numbers and impaired Ab production in vivo. Together, these data show that activated B cells require Glut1-dependent metabolic reprogramming to support proliferation and Ab production that is distinct from T cells and that this glycolytic reprogramming is regulated in tolerance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24616478      PMCID: PMC3984038          DOI: 10.4049/jimmunol.1302062

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  The CD28 signaling pathway regulates glucose metabolism.

Authors:  Kenneth A Frauwirth; James L Riley; Marian H Harris; Richard V Parry; Jeffrey C Rathmell; David R Plas; Rebecca L Elstrom; Carl H June; Craig B Thompson
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

Review 2.  Pathways for self-tolerance and the treatment of autoimmune diseases.

Authors:  C C Goodnow
Journal:  Lancet       Date:  2001-06-30       Impact factor: 79.321

3.  Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

4.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.

Authors:  I M de Alboran; R C O'Hagan; F Gärtner; B Malynn; L Davidson; R Rickert; K Rajewsky; R A DePinho; F W Alt
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

Review 5.  Cellular and genetic mechanisms of self tolerance and autoimmunity.

Authors:  Christopher C Goodnow; Jonathon Sprent; Barbara Fazekas de St Groth; Carola G Vinuesa
Journal:  Nature       Date:  2005-06-02       Impact factor: 49.962

6.  Posttranscriptional control of T cell effector function by aerobic glycolysis.

Authors:  Chih-Hao Chang; Jonathan D Curtis; Leonard B Maggi; Brandon Faubert; Alejandro V Villarino; David O'Sullivan; Stanley Ching-Cheng Huang; Gerritje J W van der Windt; Julianna Blagih; Jing Qiu; Jason D Weber; Edward J Pearce; Russell G Jones; Erika L Pearce
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

7.  Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.

Authors:  J Zhang; V Roschke; K P Baker; Z Wang; G S Alarcón; B J Fessler; H Bastian; R P Kimberly; T Zhou
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

8.  A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Authors:  Joanna Kaplon; Liang Zheng; Katrin Meissl; Barbara Chaneton; Vitaly A Selivanov; Gillian Mackay; Sjoerd H van der Burg; Elizabeth M E Verdegaal; Marta Cascante; Tomer Shlomi; Eyal Gottlieb; Daniel S Peeper
Journal:  Nature       Date:  2013-05-19       Impact factor: 49.962

9.  Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus.

Authors:  Andras Perl; Gyorgy Nagy; Peter Gergely; Ferenc Puskas; Yueming Qian; Katalin Banki
Journal:  Methods Mol Med       Date:  2004

10.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  183 in total

Review 1.  Immunometabolism: Cellular Metabolism Turns Immune Regulator.

Authors:  Róisín M Loftus; David K Finlay
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

2.  Mitochondrial Pyruvate Import Promotes Long-Term Survival of Antibody-Secreting Plasma Cells.

Authors:  Wing Y Lam; Amy M Becker; Krista M Kennerly; Rachel Wong; Jonathan D Curtis; Elizabeth M Llufrio; Kyle S McCommis; Johannes Fahrmann; Hannah A Pizzato; Ryan M Nunley; Jieun Lee; Michael J Wolfgang; Gary J Patti; Brian N Finck; Erika L Pearce; Deepta Bhattacharya
Journal:  Immunity       Date:  2016-07-05       Impact factor: 31.745

3.  Immunometabolism: From basic mechanisms to translation.

Authors:  Liza Makowski; Mehdi Chaib; Jeffrey C Rathmell
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

Review 4.  Metabolic abnormalities and oxidative stress in lupus.

Authors:  Yaima L Lightfoot; Luz P Blanco; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

5.  Comparison of the effect of the aerobic glycolysis inhibitor dichloroacetate and of the Krebs cycle inhibitor LW6 on cellular and humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Athanasios Mavropoulos; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Biomed Rep       Date:  2017-09-11

6.  Serine/threonine phosphatase PP2A is essential for optimal B cell function.

Authors:  Esra Meidan; Hao Li; Wenliang Pan; Michihito Kono; Shuilian Yu; Vasileios C Kyttaris; Christina Ioannidis; Noe Rodriguez Rodriguez; Jose C Crispin; Sokratis A Apostolidis; Pui Lee; John Manis; Amir Sharabi; Maria G Tsokos; George C Tsokos
Journal:  JCI Insight       Date:  2020-03-12

Review 7.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

8.  Functionally significant metabolic differences between B and T lymphocyte lineages.

Authors:  Jasneet Kaur Khalsa; Amanpreet Singh Chawla; Savit B Prabhu; Mukti Vats; Atika Dhar; Gagan Dev; Nabanita Das; Sandip Mukherjee; Shalini Tanwar; Hridesh Banerjee; Jeannine Marie Durdik; Vineeta Bal; Anna George; Satyajit Rath; Gopalakrishnan Aneeshkumar Arimbasseri
Journal:  Immunology       Date:  2019-08-26       Impact factor: 7.397

9.  Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Authors:  Valerie A Gerriets; Rigel J Kishton; Marc O Johnson; Sivan Cohen; Peter J Siska; Amanda G Nichols; Marc O Warmoes; Aguirre A de Cubas; Nancie J MacIver; Jason W Locasale; Laurence A Turka; Andrew D Wells; Jeffrey C Rathmell
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

10.  Suppression by TFR cells leads to durable and selective inhibition of B cell effector function.

Authors:  Peter T Sage; Noga Ron-Harel; Vikram R Juneja; Debattama R Sen; Seth Maleri; Waradon Sungnak; Vijay K Kuchroo; W Nicholas Haining; Nicolas Chevrier; Marcia Haigis; Arlene H Sharpe
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.